Drugs / Lactobacillus reuteri RC-14
Lactobacillus reuteri RC-14
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02150655 | Sep 2012 → Sep 2013 | bacterial vaginosis, vulvovaginal candidiasis | Western University, Canada | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00303082 | Jan 2006 → Jan 2009 | bacterial vaginosis, bronchopulmonary dysplasia, neonatal sepsis, periventricular leukomalacia | Oswaldo Cruz Foundation | Terminated | Missed primary Stop: Business |
| Phase 41 trial | ||||||
| Phase 4 | NCT03894813 | Mar 2019 → Dec 2020 | bacterial vaginosis | Peking University Shenzhen Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02528981 | Aug 2015 → Jun 2016 | group B streptococcal infection | Toronto Metropolitan University | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus reuteri RC-14 | “We therefore propose to study the use of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (Lactobacillus fermentum RC-14) in the colonization status of GBS in...” NCT02528981 ↗3“Oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (qd, 30 days)+Metronidazole Suppositories (qd, 7 days)” NCT03894813 ↗ “probiotic capsules containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14” PMID 29912913 ↗ Jun 2018 |
| Known as | L. reuteri RC-14 | “L. rhamnosus GR-1 and L. reuteri RC-14 will be supplied to pregnant people in gelatin capsules containing 2.5 billion viable cells of each strain (CFU).” NCT02528981 ↗ |
| Known as | Lactobacillus fermentum RC-14 | “We therefore propose to study the use of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (Lactobacillus fermentum RC-14) in the colonization status of GBS in...” NCT02528981 ↗ |
| Action | Restore | “ability of orally administered probiotic lactobacilli to restore the vaginal microbiota to a healthy state” NCT02150655 ↗ |
| Modality | Other / unclassified | “Intervention consists in the use of probiotics, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14, 2 capsules a day, each capsule containing more than one million...” PMID 20591191 ↗ Jun 2010 |
| Route | Oral | “oral administration of selected lactobacilli up to the 24th to 26th week of gestation” PMID 22059409 ↗ Nov 2011 |